

Publikationsverzeichnis Andreas Günther

Stand Juni 2009:

79 Originalarbeiten (peer reviewed; 37 hiervon als Erst- oder Seniorautor)

2 Originalarbeit in Revision

3 Korrespondenzartikel oder Briefe an den Herausgeber

26 Übersichten, Editorials oder Kommentare (19 als Erst- oder Seniorautor)

12 Buchbeiträge (11 als Erst- oder Seniorautor)

3 Lehrbuchkapitel

Originalartikel (insgesamt 78, 37 Erst- oder Seniorautorenschaften)

- 1) Seeger W, Thede C, **Günther A**, Grube C. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro - comparison to natural surfactant. [Biochim et Biophys Acta](#) 1081:45-52, 1991. IF 2,557
- 2) Seeger W, **Günther A**, Thede C. Differential sensitivity to fibrinogen-inhibition of SP-C versus SP-B based surfactants. [Am J Physiol Lung Cell Mol Physiol](#) 262:L286-L291, 1992. IF 4,214
- 3) **Günther A**, Bleyl H, Seeger W. Apoprotein-based synthetic surfactants inhibit plasminic cleavage of fibrinogen in vitro. [Am J Physiol Lung Cell Mol Physiol](#) 265:L186-192, 1993. IF 4,214
- 4) Seeger W, Elssner A, **Günther A**, Krämer HJ, Kalinowski HO. Lung surfactant phospholipids associate with polymerizing fibrin - loss of surface activity. [Am J Respir Cell Mol Biol](#) 9:213-220, 1993. IF 4,608
- 5) Seeger W, Grube C, **Günther A**. Proteolytic cleavage of fibrinogen: Amplification of its surfactant inhibitory capacity. [Am J Respir Cell Mol Biol](#) 9: 239-247, 1993. IF 4,608
- 6) Seeger W, Grube C, **Günther A**, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. [Eur Respir J](#) 6:971-977, 1993. IF 5,349
- 7) **Günther A**, Kalinowski M, Elssner A, Seeger W. Clot embedded natural surfactant: kinetics of fibrinolysis and surface activity. [Am J Physiol Lung Cell Mol Physiol](#) 267:L618-624, 1994. IF 4,214
- 8) Schröder C, **Günther A**, Seeger W, Voelter W. Synthesis and studies on the biophysical activity of human lung surfactant peptide SP-C and its n-terminal fragments. [Biomed Pept Proteins Nucleic Acids](#) 1:13-16, 1994.
- 9) **Günther A**, Kalinowski M, Rousseau S, Seeger W. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. [Am J Respir Cell Mol Biol](#) 13:712-718, 1995. IF 4,608
- 10) Krämer HJ, Schmidt R, **Günther A**, Becker G, Suzuki Y, Seeger W. Elisa technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid. [Am J Respir Crit Care Med](#) 152:1540-1544, 1995. IF 9.074
- 11) **Günther A**, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. [Am J Respir Crit Care Med](#) 153:176-184, 1996. IF 9.074
- 12) Walmrath D, **Günther A**, Schermuly RT, Schneider T, Grimminger F, Seeger W. Bronchoscopic surfactant administration in severe adult respiratory distress syndrome (ARDS). [Am J Respir Crit Care Med](#) 154:57-62, 1996. IF 9.074
- 13) Schermuly RT, Schmehl T, **Günther A**, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. [Am J Respir Crit Care Med](#) 156:445-453, 1997. IF 9.074

- 14) Rosseau S, **Günther A**, Seeger W, Lohmeyer J. Phagocytosis of viable candida albicans by alveolar macrophages: lack of opsonin function of surfactant protein A. [J Infect Dis](#) 175:421-428, 1997. IF 6,035
- 15) Kiss L, Bieneck E, Weissmann N, Schütte H, Sibelius U, **Günther A**, Bier J, Mayer K, Hennking K, Padberg W, Grimm H, Seeger W, Grimminger F. Simultaneous analysis of 4- and 5- series lipoxygenase and cytochrome P450 products from different biological sources by reversed-phase high-performance liquid chromatographic technique. [Anal Biochem](#) 261:16-18, 1998. IF 3,002
- 16) **Günther A**, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. [Eur Respir J](#) 14:565-573, 1999. IF 5,349
- 17) Steiner D, Bachmann G, **Günther A**, Bauer R. Intrathoracic Goiter. [Clin Nucl Med](#) 24:461-463, 1999. IF 3,231
- 18) **Günther A**, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W. Surfactant subtype conversion is related to loss of Surfactant Apoprotein B and surface activity in the large surfactant aggregates - experimental and clinical studies. [Am J Respir Crit Care Med](#) 159:244-251, 1999. IF 9.074
- 19) **Günther A**, Markart P, Kalinowski M, Ruppert C, Grimminger F, Seeger W. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents: kinetics of lysis and rescue of surface activity. [Am J Respir Cell Mol Biol](#) 21:738-745, 1999. IF 4,608
- 20) Rosseau S, Hammerl P, Maus U, **Günther A**, Seeger W, Lohmeyer J. Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. [J Immunol](#) 163:4495-4502, 1999. IF 6,068
- 21) **Günther A**, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbrück B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia – comparison with the Acute Respiratory Distress Syndrome. [Am J Respir Crit Care Med](#) 161:454-462, 2000. IF 9.074
- 22) **Günther A**, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. [Thromb Haemost](#) 83:853-860, 2000. IF 3,501
- 23) Schermuly RT, **Günther A**, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, Walmrath D. Differential Impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. [Am J Respir Crit Care Med](#) 161:152-159, 2000. IF 9.074
- 24) Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, **Günther A**. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome (ARDS) and severe pneumonia. [Am J Respir Crit Care Med](#) 163:95-100, 2001. IF 9.074
- 25) Schermuly RT, **Günther A**, Ermert M, Ermert L, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Walmrath D. Co-nebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. [Am J Physiol Lung Cell Mol Physiol](#) 280:L792-800, 2001. IF 4,214
- 26) Friedrich I, Spillner J, Lu EX, Bartling B, Barnscheid M, Sablotzki A, Schade U, Reidemeister JC, Silber RE, **Günther A**, Borgermann J. Ischemic preconditioning of 5 minutes but not of 10 minutes improves lung function after warm ischemia in a canine model. [J Heart Lung Transplant](#) 20:985-995, 2001. IF 3,087
- 27) Schmidt R, Steinhilber W, Ruppert C, Daum C, Grimminger F, Seeger W, **Günther A**. An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. [Am J Respir Crit Care Med](#) 165:470-474, 2002. IF 9.074
- 28) Ermert M, Ruppert C, **Günther A**, Duncker HR, Seeger W, Ermert L. Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs. [Lab Invest](#) 82:425-441, 2002. IF 4,479

- 29) **Günther A**, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, Grimminger F, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. [Eur Respir J](#) 19:797-804, 2002. IF 5,349
- 30) Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, **Günther A**, Schmehl T, Leuchte H, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. [Eur Respir J](#) 19:805-810, 2002. IF 5,349
- 31) Ruppert C, Schmidt R, Grimminger F, Suzuki Y, Seeger W, Lehr CM, **Günther A**. Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin. [Bioconjug Chem](#) 13:804-811, 2002. IF 4,384
- 32) Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, **Günther A**, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. [Lancet](#) 360:895-900, 2002. IF 28,638
- 33) Schmidt R, Meier U, Markart P, Grimminger F, Velcovsky HG, Morr H, Seeger W, **Günther A**. Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease. [Am J Physiol Lung Cell Mol Physiol](#) 283:L1079-1085, 2002. IF 4,214
- 34) Markart P, Ruppert C, Grimminger F, Seeger W, **Günther A**. Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C. [Am J Physiol Lung Cell Mol Physiol](#) 284:L69-76, 2003. IF 4,214
- 35) Weissmann N, Nollen M, Gerigk B, Ghofrani HA, Schermuly RT, **Günther A**, Quanz K, Fink L, Hänze J, Rose F, Seeger W, Grimminger F. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. [Am J Physiol Heart Circ Physiol](#) 284:H931-938, 2003. IF 3,973
- 36) Ruppert C, Pucker C, Markart P, Schmidt R, Grimminger F, Seeger W, Stürzebecher J, **Günther A**. Selective inhibition of large-to-small surfactant aggregate conversion by serine protease inhibitors of the bis-benzamidine type. [Am J Respir Cell Mol Biol](#) 28:95-102, 2003. IF 4,608
- 37) Ruppert C, Markart P, Schmidt R, Grimminger F, Seeger W, Lehr CM, **Günther A**. Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. [Thromb Haemost](#) 89:53-64, 2003. IF 3,501
- 38) Friedrich B, Schmidt R, Reiss I, **Günther A**, Seeger W, Müller M, Thul J, Schranz D, Gortner L. Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children. [Crit Care Med](#) 31:284-290, 2003. IF 6,285
- 39) Ruppert C, Pucker C, Markart P, Seibold K, Bagheri A, Grimminger F, Seeger W, **Günther A**. Impact of surface tension on the conversion rate of large to small surfactant aggregates. [Biophys Chem](#) 104:229-238, 2003. IF 1,784
- 40) Hilgendorff A, Rawer D, Doerner M, Tutdibi E, Ebsen M, Schmidt R, **Günther A**, Gortner L, Reiss I. Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. [Intens Care Med](#) 29:2247-2254, 2003. IF 4,406
- 41) **Günther A**, Lübke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. [Am J Respir Crit Care Med](#) 168:1358-1365, 2003. IF 9.074
- 42) Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, **Günther A**, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. [Am J Respir Crit Care Med](#) 169:39-45, 2004. IF 9.074
- 43) Muth H, Maus U, Wygrecka M, Lohmeyer J, Grimminger F, Seeger W, **Günther A**. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha. [Crit Care Med](#) 32:217-226, 2004. IF 6,285

- 44) Schmidt R, Schäfer C, Luboeinski T, Lockinger A, Hermle G, Grimminger F, Seeger W, Ghofrani HA, Schutte H, **Günther A**. Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. [Free Radic Biol Med](#) 36:78-89, 2004. IF 4,813
- 45) Schmidt R, Luboeinski T, Markart P, Ruppert C, Daum C, Grimminger F, Seeger W, **Günther A**. Alveolar antioxidant status in patients with acute respiratory distress syndrome. [Eur Respir J](#) 24:994-999, 2004. IF 5,349
- 46) Friedrich I, Borgermann J, Splittgerber FH, Brinkmann M, Reidemeister JC, Silber RE, Seeger W, Schmidt R, **Günther A**. Bronchoscopic surfactant administration preserves gas exchange and pulmonary compliance after single lung transplantation in dogs. [J Thorac Cardiovasc Surg](#) 127:335-343, 2004. IF 3,354
- 47) **Günther A**, Balsler M, Schmidt R, Markart P, Olk A, Borgermann J, Splittgerber FH, Seeger W, Friedrich I. Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. [J Thorac Cardiovasc Surg](#) 127:344-354, 2004. IF 3,354
- 48) Schmidt R, Ruppert C, Markart P, Lübke N, Ermert L, Weissmann N, Breithecker A, Ermert M, Seeger W, **Günther A**. Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis. [Toxicol Appl Pharmacol](#) 195:218-231, 2004. IF 3,846
- 49) Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle R, Grimminger F, Seeger W, **Günther A**. Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalative versus intravenous endotoxin application. [Thromb Haemost](#) 92:529-540, 2004. IF 3,501
- 50) Frerking I, Sengler C, **Günther A**, Walmrath D, Stevens P, Witt H, Landt O, Pison U, Nickel R. Evaluation of the -26G>A CC16 polymorphism in acute respiratory distress syndrome. [Crit Care Med](#) 33:2404-2406, 2005. IF 6,285
- 51) Greschus S, Kiessling F, Lichy MP, Moll J, Mueller M, Savai R, Rose F, Ruppert C, **Günther A**, Fusenig N, Semmler W, Traupe H. Potential applications of flat-panel volumetric CT in morphological and functional small animal imaging. [Neoplasia](#) 7:730-740, 2005. IF 5,674
- 52) [Markart P](#), [Schmidt R](#), [Ruppert C](#), [Hores C](#), [Silber RE](#), [Borgermann J](#), [Günther A](#), [Friedrich I](#). Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced surfactant alterations. [J Heart Lung Transplant](#) 24:1680-1689, 2005. IF 3,087
- 53) Hilgendorff A, Doerner M, Rawer D, Leick J, Trotter A, Ebsen M, Ruppert C, **Günther A**, Gortner L, Reiss I. Effects of a recombinant surfactant protein-C-based surfactant on lung function and the pulmonary surfactant system in a model of meconium aspiration syndrome. [Crit Care Med](#) 34:203-210, 2006. IF 6,285
- 54) Hilgendorff A, Reiss I, Ruppert C, Hanfstingl T, Seliger AS, **Günther A**, Ebsen M, Gortner L. Positive end-expiratory pressure modifies response to recombinant and natural exogenous surfactant in ventilated immature newborn rabbits. [Biol Neonate](#) 90:210-216, 2006. IF 1,904
- 55) Erpenbeck VJ, Schmidt R, **Günther A**, Krug N, Hohlfeld JM. Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma. [Allergy](#) 61:598-604, 2006. IF 5,014
- 56) Schmidt R, Markart P, Ruppert C, Temmesfeld B, Nass R, Lohmeyer J, Seeger W, **Günther A**. Pulmonary Surfactant in Patients with Pneumocystis Pneumonia and Acquired Immunodeficiency Syndrome. [Crit Care Med](#) 34:2370-2376, 2006. IF 6,285
- 57) Ruppert C, Bagheri A, Markart P, Schmidt R, Seeger W, **Günther A**. Liver carboxylesterase cleaves surfactant protein (SP-) B and promotes surfactant subtype conversion. [Biochem Biophys Res Comm](#) 348:1449-1454, 2006. IF 2,749
- 58) Bulau P, Zakrzewicz D, Kitowska K, Leiper J, **Günther A**, Grimminger F, Eickelberg O. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. [Am J Physiol Lung Cell Mol Physiol](#) 292:L18-24, 2007. IF 4,214

- 59) Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, Theruvath I, Pison U, Seeger W, **Günther A***, Witt H*. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. [Eur Respir J](#) 29:134-137, 2007. IF 5,349
- 60) **Günther A**, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stähler G, Seeger W, Grimminger F, Leconte I, Roux S, Ghofrani HA. Safety and Tolerability of bosentan in Idiopathic Pulmonary Fibrosis: an open label study. [Eur Respir J](#) 29:713-719, 2007. IF 5,349
- 61) Wygrecka M, Markart P, Ruppert C, Petri K, Preissner KT, Seeger W, **Günther A**. Cellular origin of procoagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. [Eur Respir J](#) 29:1105-1114, 2007. IF 5,349
- 62) Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, **Günther A**, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. [Proc Natl Acad Sci USA](#) 104:6388-6393, 2007. IF 9,598
- 63) Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, Harbach H, Wilhelm J, Seeger W, Schmidt R, **Günther A**. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. [Thorax](#) 62:588-594, 2007. IF 6,226
- 64) Schmidt R, Markart P, Ruppert C, Walmrath D, Seeger W, **Günther A**. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. [Respir Res](#) 8:55, 2007. IF 3,622
- 65) Wygrecka M, Morty RE, Markart P, Kanse SM, Andreasen PA, Wind T, **Günther A**, Preissner KT. Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. [J Biol Chem](#) 282:21671-21682, 2007. IF 5,581
- 66) Wygrecka M, Markart P, Fink L, **Günther A**, Preissner KT. Raised protein levels and altered cellular expression of factor VII-activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS). [Thorax](#) 62:880-888, 2007. IF 6,226
- 67) [Königshoff M](#), [Wilhelm A](#), [Jahn A](#), [Sedding D](#), [Amarie OV](#), [Eul B](#), [Seeger W](#), [Fink L](#), [Günther A](#), [Eickelberg O](#), [Rose F](#). The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. [Am J Respir Cell Mol Biol](#) 37:640-650, 2007. IF 4,608
- 68) Sadovskii J, Kuchenbuch T, Ruppert C, Fehrenbach A, Hirschburger M, Padberg W, **Günther A**, Hohlfeld JM, Fehrenbach H, Grau V. Keratinocyte growth factor prevents intra-alveolar oedema in experimental lung isografts. [Eur Respir J](#) 31:21-28, 2008. IF 5,349
- 69) Taut F, Rippin G, Schenk P, Findlay G, Wurst W, Häfner D, Lewis JF, Seeger W, **Günther A**, Spragg RG. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). [Chest](#) 134:724-732, 2008. IF 4,143
- 70) Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle RM, Seeger W, Weaver TE, **Günther A**. Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis. [Am J Respir Crit Care Med](#) 178:838-846, 2008. IF 9.074
- 71) Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, **Günther A**, Seeger W, Mayer K. Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury. [Eur Respir J](#) 32:1344-1353, 2008. IF 5,349
- 72) Hilgendorff A, Aslan E, Schaible T, Gortner L, Baehner T, Ebsen M, Kreuder J, Ruppert C, **Günther A**, Reiss I. Surfactant replacement and open lung concept - comparison of two treatment strategies in an experimental model of neonatal ARDS. [BMC Pulm Med](#) 8:10, 2008. IF 1,85
- 73) Ruppert C, Mahavadi P, Wygrecka M, Weaver T, Magdolen V, Idell S, Preissner KT, Seeger W, **Günther A***, Markart P*. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase. [Thromb Haemost](#) 100:1185-1192, 2008. IF 3,501

- 74) Markart P, Luboeinski T, Korfei M, Schmidt R, Wygrecka M, Mahavadi P, Mayer K, Wilhelm J, Seeger W, **Günther A***, Ruppert C*. Alveolar oxidative stress is associated with elevated levels of non-enzymatic low-molecular-weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases. [Antioxid Redox Signal](#) 11:227-240, 2009. IF 5,484
- 75) Mayer K, Kiessling A, Ott J, Schaefer MB, Hecker M, Henneke I, Schulz R, **Günther A**, Wang J, Wu L, Roth J, Seeger W, Kang JX. Acute lung injury is reduced in *fat-1* mice endogenously synthesizing n-3 fatty acids. [Am J Respir Crit Care Med](#) 179:474-483, 2009. IF 9.074
- 76) Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, **Günther A**, Eickelberg O. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. [J Clin Invest](#) 119:772-787, 2009. IF 16,915
- 77) Wygrecka M, Marsh LM, Morty RE, Henneke I, **Guenther A**, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. [Blood](#) 113:5588-5598, 2009. IF 10,896
- 78) Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, Rühlmann A, Weissmann N, Ghofrani HA, **Günther A**, Seeger W, Grimminger F, Morty RE, Schermuly RT. Inhibition of phosphodiesterase 4 enhances lung alveolarization in neonatal mice exposed to hyperoxia. [Eur Respir J](#) 33:861-870, 2009. IF 5,349
- 79) Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Banat GA, **Günther A**, Schermuly RT, Pullamsetti SS. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition. In press: [Mol Biol Cell](#) 2009

In Revision

- 80) Henneke I, Korfei M, Greschus S, Markart P, Schermuly RT, Wygrecka M, Stürzebecher J, Seeger W, **Guenther A**, Ruppert C, Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. [Am J Respir Crit Care Med](#). In Revision 2009
- 81) Markart P, Nass R, Ruppert C, Hundack L, Wygrecka M, Heinemann S, Korfei M, Boedeker R, Staehler G, Kroll H, Walmrath D, Scheuch G, Preissner KT, Seeger W, **Guenther A**. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. In revision: [Internat J Aerosols Med](#) 2009

Eingereicht/Submitted

- 82) Nikolova S, **Günther A**, Weissmann N, Ghofrani HA, Königshoff M, Eickelberg O, Klepetko W, Voswinckel R, Seeger W, Grimminger F, Schermuly RT, Pullamsetti SS. Phosphodiesterase 6 are expressed and altered in idiopathic pulmonary fibrosis. [Am J Respir Cell Mol Biol](#). Eingereicht Nov 2008
- 83) Pullamsetti SS, Savai R, Dumitrascu R, Kumar Dahal B, Wilhelm J, Königshoff M, Zakrzewicz D, Ghofrani HA, Weissmann N, Eickelberg O, **Guenther A**, Leiper J, Seeger W, Grimminger F, Schermuly RT. Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Eingereicht Feb 2009
- 84) Udalov SB, Dumitrascu R, Pullamsetti SS, Weissman N, Ghofrani HA, **Guenther A**, Voswinckel R, Seeger W, Grimminger F, Schermuly RT. Effects of Phosphodiesterase 4 Inhibition on Bleomycin-Induced Pulmonary Fibrosis in Mice. [PLoS One](#). Eingereicht Juli 2009
- 85) Pfaff E, Becker S, **Guenther A**; Königshoff M. Dickkopf proteins influence epithelial cell proliferation in idiopathic pulmonary fibrosis. [Eur Respir J](#). Eingereicht September 2009

* beide Autoren haben in gleichem Umfang zu der Veröffentlichung beigetragen.

Korrespondenz/Letters to the Editor

- 1) **Münster AB, Gram J, Sidelmann J, Günther A, Idell S.** Aerosolized Urokinase in Pulmonary Fibrosis. Letter to the Editor. **Am J Respir Crit Care Med** 169:1258-1259, 2004. IF 9.074
- 2) **Guenther A, Eickelberg O, Preissner KT, Chambers R, Laurent G, Wells A, Crestani B, Vancheri B, Bonniaud P, Camus P, Schmitz G, Klepetko W, Schultze J, Vossmeier D, Stumpf P.** International registry for idiopathic pulmonary fibrosis. Letter to the Editor. **Thorax** 63:841, 2008. IF 6,226
- 3) **Günther A, Taut F.** Tidal volume in mechanical ventilation: The importance of considering predicted body weight. Letter to the Editor. **Am J Respir Crit Care Med** 178:315-316, 2008. IF 9.074

Übersichten / Editorials / Kommentare

- 1) **Seeger W, Günther A, Walmrath HD, Grimminger F, Lasch HG.** Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. **Clinical Investigator** 71:177-190, 1993.
- 2) **Günther A, Elssner A, Kalinowski M, Seeger W;** The inactivation of surfactant by proteins. **Lung & Respiration** 11 (special issue):11-23, 1994.
- 3) **Seeger W, Günther A, Walmrath D, Schmidt R, Grimminger F.** Surfactanttherapie des ARDS - Hintergrund und erste klinische Erfahrungen. **Atemw.- und Lungenkrh.** 22:1996.
- 4) **Günther A** über: „Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome, N Engl J Med 334:1417-1421“, **Pneumologie** 50:769, 1996.
- 5) **Günther A** über: „Primary importance of zwitterionic over anionic phospholipids in the surface-active function of calf lung surfactant, **Am J Respir Crit Care Med** 156:1049-1057, 1997“, **Pneumologie** 52:639, 1998.
- 6) **Günther A, Walmrath D, Grimminger F, Seeger W;** Pathophysiology of Acute Lung Injury. **Seminars Respir Crit Care Med** 22:247-258, 2001. IF 1,225
- 7) **Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W;** Surfactant alteration and replacement in acute respiratory distress syndrome. **Respir Res** 2:353-364, 2001. IF 2,353
- 8) **Frerking U, Günther A, Seeger W, Pison U.** Pulmonary surfactant: functions, abnormalities and therapeutic options. **Intens Care Med** 27:1699-1717, 2001. IF 4,406
- 9) **Günther A, Ermert L, Breithecker A, Hackstein N, Eickelberg O, Morr H, Grimminger F, Velcovsky HG, Seeger W.** Klassifikation, Diagnostik und Therapie der Idiopathischen Interstitiellen Pneumonien. **Dt Ärzteblatt** 100: A1676- A1685, 2003
- 10) **Markart P, Hundack L, Ghofrani A, Grimminger F, Seeger W, Günther A.** Idiopathische Interstitielle Pneumonien: Pathomechanismen und Therapieoptionen. **Pneumologie** 59: 554-561, 2005
- 11) **Günther A, Markart P, Eickelberg O, Seeger W.** Pulmonary Fibrosis – a therapeutic dilemma? **Med Klin** 101:308-312, 2006
- 12) **Markart P, Seeger W, Günther A.** Differential therapy of pulmonary fibrosis. **Internist** 47:S26-S32, 2006. IF 0,277
- 13) **Markart P, Breithecker A, Bohle RM, Seeger W, Günther A.** Klinische, radiologische und histopathologische Kriterien zur differentialdiagnostischen Abgrenzung der exogen-allergischen Alveolitis und der nicht-spezifischen interstitiellen Pneumonie. **Allergologie** 29:470-475, 2006. IF 0,237
- 14) **Markart P, Günther A.** Kommentar zu “Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356:1317-1326, 2007” in: **Pneumonews** 1:27, 2007

- 15) **Markart P, Günther A.** Kommentar zu "Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176:277-284, 2007" in: **PneumoneWS** 1:38, 2007
- 16) **Günther A.** Perspektiven der Therapie fibrosierender Lungenerkrankungen – PMS Symposium: Perspektiven der pneumologischen Pharmakotherapie. **Arzneim-Forsch (Drug Res)** 57:736-737, 2007. IF 0,692
- 17) **Markart P, Günther A.** Kommentar zu "Idiopathic Nonspecific Interstitial Pneumonia. Lung Manifestation of Undifferentiated Connective Tissue Disease? Am J Respir Crit Care Med 176; 691-697, 2007" in: **PneumoneWS** 1:32, 2008
- 18) **Ruppert C, Markart P, Wygrecka M, Preissner KT, Günther A.** Role of coagulation and fibrinolysis in lung and renal fibrosis. **Hämostasologie** 28:30-36, 2008
- 19) **Markart P, Günther A.** Kommentar zu "BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177:75-81, 2008" in: **PneumoneWS** 2:32-33, 2008
- 20) **Markart P, Günther A.** Kommentar zu "Idiopathic Pulmonary Fibrosis. Outcome in Relation to Smoking Status. Am J Respir Crit Care Med 177:190-194, 2008" in: **PneumoneWS** 3:14-15, 2008
- 21) **Wygrecka M, Jablonska E, Günther A, Preissner KT, Markart P.** Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. **Thromb Haemost** 99:494-501, 2008. IF 3,501
- 22) **Ruppert C, Seeger W, Günther A.** Surfactant in ARDS. **The Lung Perspectives** 16: 6-73 2008.
- 23) **Markart P, Günther A.** Kommentar zu „Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice" Eur Respir J 2008;32:426-36 in: **PneumoNews** 5:32,2008
- 24) **Markart P, Günther A.** Kommentar zu „Short telomers are a risk factor for idiopathic pulmonary fibrosis" PNAS 2008;105:13051-56 in **PneumoNews** 6:33,2008
- 25) **Markart P, Günther A.** Kommentar zu „Seasonal variation: Mortality from pulmonary fibrosis is greatest in the winter" Chest 2008 Aug 8 in **PneumoNews** 3:19,2009
- 26) **Markart P, Günther A.** Kommentar zu „Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis" Am J Respir Crit Care Med 2009;179:717-23 in **PneumoNews** 4:27,2009

Buchbeiträge

- 1) **Günther A, Grube C, Seeger W;** Inhibition of surfactant by plasma proteins; *in:* **Surfactant in clinical practice** (G. Bevilaqua, S. Parmigiani, B. Robertson, Ed.), Harwood Academic Publishers; Chur, Switzerland; 87-102, 1992.
- 2) **Seeger W, Günther A;** Surfactant and adult respiratory distress syndrome; *in:* **Progress in Respiration Research: Lung Surfactant: Basic research in the pathogenesis of lung disorders.** (H. Herzog, Ed.). Karger Basel 222-231, 1994
- 3) **Günther A, Seeger W;** Resistance to surfactant inactivation; *in:* **Surfactant Therapy for Lung Disease** (B. Robertson und H. W. Taeusch, Ed.) Marcel Dekker, New York, 269-292, 1995.
- 4) **Günther A, Walmrath D, Grimminger F, Seeger W;** Alteration of pulmonary surfactant in adult respiratory distress syndrome: effects of a transbronchial surfactant application; *in:* **Advances in perinatal medicine** (F. Cockburn, Ed.). Parthenon Publishing Group, New York, London, 328-330, 1997.
- 5) **Seeger W, Günther A, Walmrath D.** Alveolar Surfactant and ARDS; *in:* **Update in Intensive Care and Emergency Medicine: Acute Lung Injury** (J.J. Marini und T. W. Evans, Ed.). Springer Verlag Berlin, Heidelberg, New York, 88-106, 1998.

- 6) **Seeger W, Günther A**; Pulmonary Surfactant; *in*: **Oxford Handbook of Critical Care Medicine** (A. R. Webb, M. J. Shapiro, M. Singer und P. M. Suter, Ed.) Oxford University Press, Oxford, 1280-1282, 1999.
- 7) **Günther A, Walmrath D, Grimminger F, Seeger W**; Alteration of Pulmonary Surfactant in ARDS - Pathogenetic Role and Therapeutic Perspectives; *in*: **Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management** (S. Matalon und J. I. Sznajder, Ed.). Plenum Press New York, 97-105, 1998.
- 8) **Günther A, Walmrath D, Grimminger F, Grimminger F**; Surfactant metabolism and replacement in ARDS; *in*: **European Respiratory Monograph** Vol 7, Monograph 20: Acute Respiratory Distress Syndrome (T.W. Evans, M.J.D. Griffiths and B. F. Keogh, Ed.). European Respiratory Society Sheffield, UK, 119-128, 2002.
- 9) **Ruppert C, Seeger W, Günther A**; Prospects for reduction of ventilator-induced lung injury with surfactant; *in*: **Lung Biology in Health and Disease: Ventilator-induced lung injury** (D. Dreyfuss, G. Saumon and R. Hubmayr, Ed.). Taylor & Francis, New York, 2006.
- 10) **Günther A, Ruppert C**; Anticoagulants; *in*: **Encyclopedia of Respiratory Medicine** (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.
- 11) **Günther A, Ruppert C**; Coagulation Cascade: Fibrinogen and Fibrin; *in*: **Encyclopedia of Respiratory Medicine** (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.
- 12) **Günther A, Ruppert C**; Coagulation Cascade: Antithrombin III; *in*: **Encyclopedia of Respiratory Medicine** (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.

Lehrbuchkapitel

- 1) **Seeger W, Günther A**; Pulmonary Surfactant; *in*: **Oxford Handbook of Critical Care Medicine** (A. R. Webb, M. J. Shapiro, M. Singer und P. M. Suter, Ed.) Oxford University Press, Oxford, 1280-1282, 1999.
- 2) **A Günther, F Grimminger, W Seeger**. Interstitielle Lungenerkrankungen, *in*: **Lehrbuch Innere Medizin**, 6. Auflage (CDK Classen/Diehl/Kochsiek - Böhm/Hallek/Schmiegel, Hrsg.), Elsevier Verlag, München. Im Druck 2008.
- 3) **A Günther**. Diffus parenchymatöse Lungenerkrankungen, *in*: **Klinische Pneumologie**, 4. Auflage (Matthys, Seeger, Hrsg.), Springer Verlag, Heidelberg Berlin, 373-394, 2008.

* beide Autoren haben in gleichem Umfang zu der Veröffentlichung beigetragen.